Collegium Pharmaceutical (COLL) EBIT (2014 - 2026)

Collegium Pharmaceutical's EBIT history runs 13 years deep, the most recent figure standing at $30.9 million for Q1 2026.

• In Q1 2026, EBIT rose 42.46% year-over-year to $30.9 million; the TTM figure through Mar 2026 stood at $188.8 million (up 32.89% YoY), while the FY2025 annual figure was $179.6 million, up 5.73% from the prior year.
• EBIT was $30.9 million for Q1 2026 at Collegium Pharmaceutical, down from $60.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $62.1 million in Q3 2025 to a low of -$10.0 million in Q1 2022.
• Historically, EBIT has averaged $34.2 million across 5 years, with a median of $35.1 million in 2025.
• The sharpest annual moves came in 2022 and 2023: EBIT plunged 147.26% in 2022, then surged 424.69% in 2023.
• A 5-year view of EBIT shows it stood at $11.8 million in 2022, then soared by 424.69% to $61.7 million in 2023, then plunged by 38.22% to $38.1 million in 2024, then surged by 59.42% to $60.8 million in 2025, then tumbled by 49.15% to $30.9 million in 2026.
• The last three EBIT figures came in at $30.9 million (Q1 2026), $60.8 million (Q4 2025), and $62.1 million (Q3 2025), per Business Quant data.